机构:[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines, CAMS Key Laboratory of Molecular Mechanism and Target Discovery of Metabolic Disorder and Tumorigenesis, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[2]Sichuan Engineering Research Center for Medicinal Animals, Sichuan, China.[3]Department of Chemistry of Medicinal Natural Products, West China College of Pharmacy, Sichuan University, Sichuan, China.[4]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Sichuan, China.四川大学华西医院
National Key R&D
Program of China (2017YFA0205400), the National Natural Science
Foundation of China (81773800), Chinese Academy ofMedical Sciences
(CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-016, 2022-
I2M-JB-009), the Beijing Outstanding Young Scientist Program
(BJJWZYJH01201910023028), Chinese Academy of Medical Sciences
(CAMS) Central Public-interest Scientific Institution Basal Research
Fund (2018PT35004, Molecular Mechanism and Target Discovery of
Metabolic Disorder and Tumorigenesis, CAMS Key Laboratory), and the
Special Research Fund for Central Universities, Peking Union Medical
College (3332021043).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|2 区药学
最新[2023]版:
大类|2 区医学
小类|2 区药学
第一作者:
第一作者机构:[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines, CAMS Key Laboratory of Molecular Mechanism and Target Discovery of Metabolic Disorder and Tumorigenesis, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
共同第一作者:
通讯作者:
通讯机构:[2]Sichuan Engineering Research Center for Medicinal Animals, Sichuan, China.[4]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Sichuan, China.
推荐引用方式(GB/T 7714):
Zhou Ji-Chao,Jin Cai-Cai,Wei Xiao-Li,et al.Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy[J].Frontiers in pharmacology.2023,14:1118017.doi:10.3389/fphar.2023.1118017.
APA:
Zhou Ji-Chao,Jin Cai-Cai,Wei Xiao-Li,Xu Rui-Bing,Wang Ruo-Yu...&Zhang Xiao-Wei.(2023).Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy.Frontiers in pharmacology,14,
MLA:
Zhou Ji-Chao,et al."Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy".Frontiers in pharmacology 14.(2023):1118017